Coldstream Capital Management Inc. Increases Holdings in Abbott Laboratories $ABT

Coldstream Capital Management Inc. boosted its position in Abbott Laboratories (NYSE:ABT) by 11.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 93,196 shares of the healthcare product maker’s stock after buying an additional 9,625 shares during the period. Coldstream Capital Management Inc.’s holdings in Abbott Laboratories were worth $12,483,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories during the 3rd quarter valued at approximately $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories in the third quarter worth $31,000. Anfield Capital Management LLC raised its holdings in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares during the last quarter. Delos Wealth Advisors LLC acquired a new position in Abbott Laboratories during the second quarter valued at $32,000. Finally, Bridge Generations Wealth Management LLC purchased a new stake in Abbott Laboratories in the third quarter valued at $33,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ABT shares. Daiwa Securities Group cut their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Evercore lowered their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Finally, BTIG Research decreased their price target on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $136.16.

Insider Buying and Selling at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 585 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares of the company’s stock, valued at $2,846,504.24. This represents a 2.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. This represents a 0.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Trading Up 0.8%

Shares of Abbott Laboratories stock opened at $110.80 on Wednesday. The firm has a 50-day simple moving average of $113.91 and a two-hundred day simple moving average of $123.50. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $139.06. The company has a market cap of $192.98 billion, a P/E ratio of 29.79, a price-to-earnings-growth ratio of 1.75 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.